Cargando…

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells

BACKGROUND: A major problem with cisplatin treatment is the development of acquired-drug resistance of the tumour cells. Verotoxin-1 (VT-1) exerts its cytotoxicity by targeting the membrane glycolipid globotriasosylceramide (Gb3), a molecule associated with drug resistance. Cisplatin- and VT-1-induc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johansson, D, Andersson, C, Moharer, J, Johansson, A, Behnam-Motlagh, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2816648/ https://www.ncbi.nlm.nih.gov/pubmed/20010943 http://dx.doi.org/10.1038/sj.bjc.6605467

Ejemplares similares

Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis
por: Johansson, David, et al.
Publicado: (2009)

Verotoxin-1 Treatment or Manipulation of its Receptor Globotriaosylceramide (Gb3) for Reversal of Multidrug Resistance to Cancer Chemotherapy
por: Behnam-Motlagh, Parviz, et al.
Publicado: (2010)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma
por: Ghanim, B, et al.
Publicado: (2014)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
por: Hoda, M A, et al.
Publicado: (2012)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance
por: Janson, V, et al.
Publicado: (2010)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma
por: Borchert, Sabrina, et al.
Publicado: (2020)

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
por: Kao, Steven C, et al.
Publicado: (2016)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
por: Goudar, Ranjit K
Publicado: (2008)

Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo
por: Gassler, N, et al.
Publicado: (2005)

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients
por: Jennings, C J, et al.
Publicado: (2015)

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
por: McPherson, R A C, et al.
Publicado: (2009)

Nicotine increases the resistance of lung cancer cells to cisplatin through enhancing Bcl-2 stability
por: Nishioka, T, et al.
Publicado: (2014)

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes
por: Teng, P-N, et al.
Publicado: (2014)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
por: van Haarst, J M W, et al.
Publicado: (2002)

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
por: Dalton, L E, et al.
Publicado: (2013)

The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro
por: O'Brien, P M, et al.
Publicado: (2008)

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
por: Sørensen, J B, et al.
Publicado: (2008)

SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2022)

Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
por: Kamoshida, S, et al.
Publicado: (2007)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models
por: Oliva, P, et al.
Publicado: (2012)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes
por: Papazoglou, Eleftherios D., et al.
Publicado: (2019)

REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer
por: Sekikawa, A, et al.
Publicado: (2013)

Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions
por: Brismar-Wendel, S, et al.
Publicado: (2009)

SV40 associated miRNAs are not detectable in mesotheliomas
por: Gee, G V, et al.
Publicado: (2010)

Evaluating the effect of immune cells on the outcome of patients with mesothelioma
por: Chee, Serena J, et al.
Publicado: (2017)

Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma
por: Denis, Iza, et al.
Publicado: (2014)

Markers for the non-invasive diagnosis of mesothelioma: a systematic review
por: van der Bij, S, et al.
Publicado: (2011)

Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN)
por: Andersson, S, et al.
Publicado: (2005)

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
por: Lee, S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_5o7okt12e3p6kudm9j8hl02hlt